These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30915162)

  • 41. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches.
    Dilmac S; Ozpolat B
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    Lu Z; Mao W; Yang H; Santiago-O'Farrill JM; Rask PJ; Mondal J; Chen H; Ivan C; Liu X; Liu CG; Xi Y; Masuda K; Carrami EM; Chen M; Tang Y; Pang L; Lakomy DS; Calin GA; Liang H; Ahmed AA; Vankayalapati H; Bast RC
    J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35642638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
    Rubinstein WS
    Fam Cancer; 2008; 7(1):83-9. PubMed ID: 17624601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of hereditary breast and ovarian cancer.
    Yamauchi H; Takei J
    Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast Cancer Predisposition Genes and Synthetic Lethality.
    Neiger HE; Siegler EL; Shi Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
    [No Abstract]   [Full Text] [Related]  

  • 48. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PARP inhibitors in ovarian cancer.
    Ledermann JA
    Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current practices on genetic testing in ovarian cancer.
    Fostira F; Papadimitriou M; Papadimitriou C
    Ann Transl Med; 2020 Dec; 8(24):1703. PubMed ID: 33490215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
    Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
    Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
    Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
    J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The DNA damaging revolution.
    Cetin B; Wabl CA; Gumusay O
    Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
    Oh SY; Rahman S; Sparano JA
    Expert Opin Pharmacother; 2021 Jun; 22(8):981-1003. PubMed ID: 33646064
    [No Abstract]   [Full Text] [Related]  

  • 59. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
    Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.